aod9604 mechanism of action inhibits lipogenesis

aod9604 mechanism of action inhibits lipogenesis GADD45β hepatic through the AMPK/SREBP1 pathway via reducing the ubiquitination-mediated degradation SIRT1 ANXA1 inhibits ferroptosis in HUVECs

Name: aod9604 mechanism of action inhibits lipogenesis GADD45β hepatic through the AMPK/SREBP1 pathway via reducing the ubiquitination-mediated degradation SIRT1 ANXA1 inhibits ferroptosis in HUVECs
Brand: www.asociacionchamorro.org
SKU: 12245894486
Price: 21.00 USD
Availability: InStock
Rating: 4.540900000000001 (10 reviews)

ANXA1 inhibits ferroptosis in HUVECs via negative regulation of ferritinophagy ScienceDirect Frontiers Manifold hepatoprotective actions of lipoic acid on metabolic function through redox regulation, inflammatory modulation, and anti apoptosis after chronic sleep deprived injury Physiological and pathological roles of lipogenesis Nature Metabolism In depth analysis of de novo lipogenesis in non alcoholic fatty liver disease: Mechanism and pharmacological interventions ScienceDirect

SKU: 12245894486 · From www.asociacionchamorro.org

4.5

USD21.00 USD54.00

Pay in 4 interest-free payments of $5.25 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 19 - Aug 24

Description

The peptide has a very short plasma half-life of approximately 3 minutes, which influences dosing frequency and timing considerations

aod9604 mechanism of action inhibits lipogenesis GADD45 hepatic through the AMPK/SREBP1 pathway via reducing the ubiquitination-mediated degradation SIRT1 ANXA1 inhibits ferroptosis in HUVECs

(1) M Heffernan, R J Summers, A Thorburn, E Ogru, et al (2001) The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice Endocrinology, 2001 Dec, Volume 142 (Issue 12), Pages 5182-9